Abiopharma

Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance

New Form 8-K - Shattuck Labs, Inc. Filed: 2025-08-05 AccNo: 0001193125-25-173010 Size: 842 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes USA - English India - English

New Form 6-K - SOPHiA GENETICS SA Filed: 2025-08-05 AccNo: 0001840706-25-000026 Size: 5 MB

New Form 10-Q - RECURSION PHARMACEUTICALS, INC. Filed: 2025-08-05 AccNo: 0001601830-25-000127 Size: 9 MB

Avanos Medical, Inc. Announces Second Quarter 2025 Results

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Shattuck Labs - Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

Westlake - Westlake Corporation Reports Second Quarter 2025 Results

InfuSystem Reports Second Quarter 2025 Financial Results

Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025

Compass Pathways - Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA

Westlake - Westlake Chemical Partners LP Announces Second Quarter 2025 Results

New Form 8-K - InfuSystem Holdings, Inc Filed: 2025-08-05 AccNo: 0001628280-25-037582 Size: 1 MB Item 2.02: Results of Operations and Financial Condition

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million